Yahoo
OTC Markets OTCQB - Delayed Quote USD

CERo Therapeutics Holdings, Inc. (CERO)

0.0060 +0.0010 (+20.00%)
At close: 3:20:32 PM EDT
Chart Range Bar
Loading chart for CERO
  • Previous Close 0.0050
  • Open 0.0048
  • Bid 0.0057 x 7000000
  • Ask 0.0060 x 6000000
  • Day's Range 0.0048 - 0.0060
  • 52 Week Range 0.0040 - 2.0000
  • Volume 140,427
  • Avg. Volume 589,668
  • Market Cap (intraday) 429,785
  • Beta (5Y Monthly) 0.22
  • PE Ratio (TTM) 0.00
  • EPS (TTM) 40.3400
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

www.cero.bio

8

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/26/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CERO
91.04%
S&P 500 (^GSPC)
12.14%

1-Year Return

CERO
99.69%
S&P 500 (^GSPC)
13.03%

3-Year Return

CERO
100.00%
S&P 500 (^GSPC)
85.55%

5-Year Return

CERO
100.00%
S&P 500 (^GSPC)
67.81%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -48.45M
Profit Margin 0.00%

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-40M
-30M
-20M
-10M
0
0.0%

Statistics

View More

Valuation Measures

Annual
As of 10/23/2026
  • Market Cap

    343.83k

  • Enterprise Value

    1.66M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -279.03%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -95.3M

  • Diluted EPS (ttm)

    40.3400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    862.76k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    4.01M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

0.0060 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: